ABOUT this BLOG and How to use it

WELCOME to Stu's Views & MS News. A product of MS Views and News, a Not-for-Profit [501c3] organization. Founded in 2008, we provide educational Multiple Sclerosis information via live seminars and via the internet.

Key-Notes: Our live seminars average approx 60 people per educational program. Our blog is visited over 2900 times per week and our website is visited by thousands each month.

Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in (90) Countries.

On this blog see our Directory, Archives, recent Blog Posts & so much more. Use the Blog Search box (enter a keyword). See our Facebook information AND Links to other MS Organizations & bloggers. Scroll through entire page, to find information that could EMPOWER You. At the Bottom of this page, see informational videos and some for fun.

Disclaimer: "Stu's Views & MS News" / 'MS Views and News' does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Like this blog? - CLICK "LIKE"

Monday, April 4, 2011

Gilenya Update


written by: Cherie C. Binns RN BS MSCN
April 4, 2011



I attended a patient education program on Gilenya today presented by a nurse educator from Novartis and two local neurologists.
We heard that in the 6 months since Gilenya went on the market, there are 500 persons currently taking it.
It impacts liver function tests more negatively than any of the interferons so if a person had to go off an interferon due to elevated liver function Tests (LFTs) they will probably not so well on Gilenya.
One can transition directly from one of the injectable medications to Gilenya without a waiting period.
Persons on Tysabri need a minimum of 3-6 months with no Tysabri or steroids before being considered to start Gilenya.
Persons taking monthly IVSM need to miss at least one dose prior to going on Gilenya (off two months from last dose)
Persons taking CellCept, Immuran, Methotrexate or Cytoxan will have to wait 3-6 months before being considered eligible for Gilenya.
If a patient has not had chickenpox, they must have the vaccine and wait one month after receiving it to start Gilenya.
EKG and Ophthalmic exam looking for Macular edema must be done prior to drug administration.
Person must take first dose in Dr. Office or infusion Center when they can have cardiac monitoring and hourly vital signs done as first degree heart block can happen with the initial dose.
A follow up Ophthalmic exam must be done at 4 months into dosing to rule out macular edema.
The drug costs $4000/month and most private insurances will pay for it but so far Medicare and Medicaid are not.   Novartis is offering up to $800/month to each person to help cover copays.   So if you have Blue Cross and your Copay for one of the injectables is $75/month, you will have your copay covered by Novartis.  Pre-approval is mandatory.
Because there is currently no approved medication on the market for progressive non-relapsing forms of MS, now that this drug is FDA approved, it might be tried on an individual basis if a patient's Dr. feels their condition warrants trying this drug.
Most patients (up to 90%) have headaches or GI disturbances with this medication (diarrhea or nausea).   Some have flu-like symptoms but they are less prominent with this medication than with the interferons.
You are free to post this information and have anyone with further questions contact their neurologist for answers that are specific to their needs.
Cherie C. Binns RN BS MSCN



====================
****************************************************************
Remain CURRENT with Multiple Sclerosis information 
 when registered at the  MS Views and News  website
.
***************************************************************************************
Help to Educate:  Please donate   - all contributions are tax deductible - 
.
"Providing You with 'MS Views and News'is what we do"
***************************************************************************************
.
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
 ****************************************************************

2 comments:

Stuart said...

Cherie,

THIS Sounds like very negative news about Gilenya and yet, it was presented by Novartis ?

Regards,

Stuart

Anonymous said...

Stuart,


Yes. Novartis had a nurse educator and neurologist there , and provided lunch for about 40-50 of us. Dr. Salvatore Napoli, the medical director of the MS Dream Center in Cranston RI came to answer questions during the lunch hour just prior to the presentation and he basically "took all my questions" (from the doc hired by Novartis).

They all voiced great concern about people using Tysabri, Mitoxantrone, Cytoxan as therapies ever being able to be off their med long enough and safely enough to make it to use of Gilenya. Side effect profile is high. They did stress that, although 6 patients had died in the phase III trial, none were in the 0.5mg arm of the trial which was the dose passed by the FDA.

Cherie
cheriebinns@verizon.net

PS: The nurse educator was Kim-Marie Nichols, RN MSCN and her email is kim.nichols@novartis.com if you wish to confirm any of what I have written.